Mainboard · BSE and NSEDraft filed
Claroid Pharmaceuticals Limited IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- 1,26,00,000 shares (Amount not stated in the draft)
- DRHP dated Tue 22 Sep 2026, page 79
- Bid dates
- Not announced
- Listing date
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedWed 30 Sep 2026 confirmedDRHP dated Tue 22 Sep 2026
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Objects of the issue
| Object | Amount |
|---|---|
| Funding of capital expenditure requirement for setting up of the Proposed Plant | ₹167.97 crore |
| General Corporate Purposes | Not stated in the draft |
| Total | Not stated in the draft |
The offer for sale goes to the selling shareholders, not the company. DRHP dated Tue 22 Sep 2026, page 125
Company and promoters
As described in the DRHP
We are a pharmaceutical formulations manufacturing company engaged in the development and manufacture of generic pharmaceutical products, comprising tablets and ointments and the encapsulation of pharmaceuticals formulations into hard gelatin capsules. Our business model is primarily focused on export of pharmaceutical products to semi-regulated international markets, particularly in Africa.
DRHP dated Tue 22 Sep 2026, page 255
Promoters
- 5 individual promoters
DRHP dated Tue 22 Sep 2026, page 326
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 100% | Not stated in the DRHP |
DRHP dated Tue 22 Sep 2026, page 118
Financials (restated)
| Item | Fiscal 2026 | Fiscal 2025 | Fiscal 2024 |
|---|---|---|---|
| Revenue from operations | ₹169.72 crore | ₹99.70 crore | ₹63.00 crore |
| Profit after tax | ₹22.70 crore | ₹7.22 crore | ₹4.12 crore |
| Net worth | ₹44.38 crore | ₹21.69 crore | ₹14.47 crore |
| Total borrowings | Not stated in the draft | Not stated in the draft | Not stated in the draft |
DRHP dated Tue 22 Sep 2026, page 84
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Individual shareholder | Individual | 10,55,750 | Not announced |
| Individual shareholder | Individual | 4,73,800 | Not announced |
| Individual shareholder | Individual | 9,78,500 | Not announced |
| Individual shareholder | Individual | 9,61,332 | Not announced |
| Individual shareholder | Individual | 9,85,367 | Not announced |
| Individual shareholder | Individual | 5,06,416 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,166 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,166 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Individual shareholder | Individual | 17,167 | Not announced |
| Total offer for sale | Not stated in the draft | ||
DRHP dated Tue 22 Sep 2026, page 79
Peer comparison (as in the DRHP)
| Name of the Company | Consolidated/ Standalone | Revenue from Operations (₹ in Lakhs) | Face Value per equity share (₹) | Market Price | EPS (Basic and Diluted) (₹) | P/E ratio | RoNW (%) | NAV (per equity share) (₹) |
|---|---|---|---|---|---|---|---|---|
| Claroid Pharmaceuticals Limited | Standalone | 16,971.53 | 10 | [●] | 5.41 | [●] | 51.16% | 10.57 |
| Bafna Pharmaceuticals Ltd | Standalone | 15,061.74 | 10 | 329* | 4.69 | 99.90* | 15.31% | 40.64 |
| Syncom Formulations (India) Ltd | Consolidated | 48,917.15 | 1 | 19.80* | 0.81 | 21.90* | 20.21% | 4.41 |
| Lincoln Pharmaceuticals Ltd | Consolidated | 67,102.99 | 10 | 606* | 43.88 | 12.60* | 11.80% | 378.25 |
Reproduced from the DRHP dated Tue 22 Sep 2026, page 187; InsightPier adds no figures
Risk factors
74 total- Most revenue comes from exports to Nigeria, so problems in Nigeria or in India-Nigeria trade could hurt the business (DRHP page 33)
- The top ten customers provide most product sales; losing any of them could hurt results (DRHP page 34)
- Tablets make up about half of product sales; trouble in this segment could hurt the business (DRHP page 35)
- Heavy reliance on exports exposes the company to international business risks (DRHP page 36)
- Failure to obtain or renew licences and approvals, or changes in regulation, could hurt operations (DRHP page 37)